Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT06921850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06921850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 7, 2025
Completion date
March 6, 2029
Enrollment
43 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa